Evidence map›Paper›PMID 1837777›Full record

ReviewEnvironmental health perspectives1991

Mechanisms of oncogene cooperation: activation and inactivation of a growth antagonist.

M M Ragozzino, A Kuo, J DeGregori, N Kohl, H E Ruley

Abstract readReview
In one paragraph

Review in Environmental health perspectives, 1991. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Oncogenic H-Ras V12 promotes anchorage-independent cytokinesis in human fibroblasts.Proceedings of the National Academy of Sciences of the United States of America · 2007
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

M M RagozzinoCenter for Cancer Research, Massachusetts Institute of Technology, Cambridge 02139.
A Kuo
J DeGregori
N Kohl
H E Ruley

Funding

VIRUS PRODUCTION COREP30CA014051 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI MATTHEW G. VANDER HEIDEN · 1985 to 2026
$93.9M
USE OF RETROVIRUS PROMOTER TRAP VECTORS TO IDENTIFY ONCOGENES AND ANTI-ONCOGENESP01CA042063 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI JACKS, TYLER E. · 1986 to 2021
$30.5M
ONCOGENE COLLABORATIONS IN CELL TRANSFORMATIONSR01CA040602 · NCI · VANDERBILT UNIVERSITY · PI RULEY, HENRY EARL · 1985 to 1992
–
NCI NIH HHS P01CA42063NCI NIH HHS P30CA14051NCI NIH HHS R01CA40602
6 · The paper itself

Abstract

Gene transfer experiments have defined limitations with regard to the ability of individual oncogenes to transform cultured cells to a tumorigenic state. The stable transformation of REF52 cells by either the ras or sis oncogenes requires the continuous expression of a second collaborating oncogene, such as adenovirus-5 E1A or SV40 large T-antigen. Our studies suggest that the function of the nuclear collaborators is to antagonize dominant growth controls which limit the ability of REF52 cells to proliferate in response to mitogenic stimuli.

Indexed as

Epistasis, GeneticGene Expression Regulation, NeoplasticOncogenesAdenovirus Early ProteinsAnimalsAntigens, Polyomavirus TransformingCell LineCell Line, TransformedCell Transformation, NeoplasticCricetinaeFibroblastsGenes, rasGenes, RetinoblastomaGenetic Complementation TestHybrid CellsMesocricetusAdenovirus Early ProteinsAntigens, Polyomavirus TransformingOncogene Proteins, ViralPlatelet-Derived Growth FactorProto-Oncogene ProteinsProto-Oncogene Proteins c-sisProto-Oncogene Proteins p21(ras)

Identifiers

PMID1837777
PMCPMC1568054

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.